Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

But as of Q2, it has approximately $1.4 billion in cash, cash equivalents, and marketable investments on hand, and a pipeline that's chock-full of clinical-stage candidates that use GLP-1 and ...

Dr. Arun Swaminathan, Coya’s Chief Business Officer, stated, “There has been an upswing in interest from major pharma companies looking to expand their GLP-1 RA pipeline including testing ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

And with a full obesity pipeline of promise, I’d pin Lilly’s odds of long-term GLP-1 domination as pretty high. Given the ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

Here's what doctors think about them. Weight loss with Ozempic or Wegovy can be effective, but expensive. Enter so-called GLP-1 supplements that have taken on the nickname “nature’s Ozempic.” They’re ...

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...